Novo Nordisk plans Phase 3 clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist, investigating both injectable and oral formulations. The move comes after positive phase 1b/2a data demonstrating significant weight loss. Initiation is slated for early 2026, aiming to expand options beyond current obesity treatments amid competitive market dynamics.